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Summary
To develop a model of human thymus growth in vivo, we have implanted postnatal human thymus
under the renal capsule of severe combined immune deficient (SCID) mice and assayed for graft
survival and graft characteristics 1-3 mo after engraftment. Three groups of SCID mice were
engrafted with postnatal human thymus: untreated SCID mice, SCID mice pretreated with 400
cGy ofy irradiation 1-5 d before engraftment, and SCID mice treated with intraperitoneal anti-asialo
GM-1 antiserum every 4-5 d during engraftment. In the untreated group of SCID mice, only
37% ofgrafts survived and consisted ofhuman thymic microenvironment components and human
immature thymocytes. Irradiation ofSCID mice before engraftment improved survival of human
thymic grafts to 83%, but these grafts were largely devoid of thymocytes and contained only
thymic microenvironment components with large numbers of thymic macrophages. Treatment
of SCID mice with anti-asialo GM-1 antiserum throughout the engraftment period also promoted
human thymus engraftment (70%) and induced SCID B cell Ig production (SCID[Ig+]) in 38%
of animals. In SCID(Ig - ) anti-asialo GM-1-treated mice, the human thymic grafts were similar
in content to those in untreated SCID mice. However, in anti-asialo GM-1-treated animals with
grafts that became SCID(Ig+), all animals were found to have mouse-human chimeric grafts
in that the human thymic microenvironment (human fibroblasts, thymic epithelium, vessels)
was colonized by murine T cells. These data demonstrate that human postnatal thymus will
grow as xenografts in SCID mice, and that the components of human thymus that engraft are
dependent on the immunosuppressive regimen used in recipient mice. A striking finding in this
study was the induction of T and B lymphopoiesis in SCID mice by abrogation of NK cell
activity with in vivo anti-asialo GM-1 treatment. These data strongly suggest that asialo GM-1'
NK cells and/or macrophages play a role in mediation ofsuppression of lymphopoiesis in SCID mice.
cent studies have begun to clarify the early stages of
human T cell maturation (1-5). However, a major
problem remains in the study of the human T cell lineage
in that the intact thymic microenvironment is necessary for
T cell precursors to mature through all stages of normal T
cell development. The essential requirement of the microen-
vironment in T cell ontogeny necessitates that the compo-
nents of thymic stroma be present in models of T lineage
development . The use of animal models of T cell develop-
ment have provided powerful systems to unravel complex cel-
lular interactions that occur in thymic development (6, 7).
What is needed in the study of human T cell maturation
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is a model system that allows for analysis ofthymocyte-thymic
microenvironment interactions that occur in vivo.
In 1988, McCune et al. (8) described a system in which
human fetal thymic and fetal liver grafts grew in C.B-17
scid/scid (SCID) mice. In the SCID-hu model of McCune
et al. (8), a reduction in the growth potential of thymic
xenografts was observed when donor human thymic tissue
was >20 wk of gestational age. Unlike human fetal tissue
that is not routinely available to most investigators, postnatal
human thymic tissue is available as discarded tissue, removed
to expose the heart in select pediatric corrective cardiovas-
cular surgical procedures.
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plants of human postnatal thymus in SCID mice. We dem-
onstrate that humanpostnatal thymus will grow as xenografts
in SCID mice, and that the components of human thymus
engrafted vary with the immunosuppressive regimen given
to the SCID mouse recipient. Whereas grafts in untreated
animals contained both humanmicroenvironment and thymo-
cyte components, grafts in animals irradiated with 400 cGy
before engraftment contained predominantly thymic microen-
vironment components only. When SCID mice were treated
with anti-asialo GM-1, an antiserum against murine NK cells
and macrophages, 38% of animals were induced to produce
murine Ig (i.e., became SCID[Ig+] [9]). In this group of
SCID(Ig') mice, human thymic grafts grew well, were
highly lymphoid, but, in contrast to untreated and irradi-
ated SCID recipients, contained human thymic microenviron-
ment components that were populated by murine T cells.
Materials and Methods
Animals.
￿
Breederpairs of SCID (10) mice were obtained from
TheJackson Laboratory (Bar Harbor, ME) from the colony of L.
Shultz, andwere bred andmaintained underpathogen-free condi-
tionsin theanimal barrierfacility at the Duke University Vivarium.
Mice were housed in microisolator cages, andallfood, caging, and
beddingwere autoclaved before use. Mice received daily trimetho-
prim/sulfamethoxazolein suspension in drinking water(40 mg tri-
methoprimand 200mg sulfamethoxazole per 320 ml of drinking
water). All mice used were between 8 and 19 wk of age.
Placement ofHuman Thymic Xenografts in SCID Mice.
￿
Human
postnatal thymic tissue (age, 1 d to 14 mo)was obtained from pa-
tients undergoing correctivecardiovascular surgical procedures that
require removal of thymic tissue forheartexposure.Thymic tissue
was either used immediately for implantation into SCID mice or
frozen in RPMI 1640 + 7.5% dimethyl sulfoxide + 15% FCS,
and stored in liquid nitrogen for future use.
Forengraftment of humanthymic tissue into SCID mice, male
and female SCID mice were anesthetized with a 1:1 mixture of
Ketamine, 5 mg/ml(Aveco, Fort Dodge, IA)andXylazine, 5 mg/
ml, (Mobay, Shawnee, KA) at the dosage of 0.05 mg/gm. A2-cm
right flankincision wasmade and thekidney exteriorized. Human
postnatal thymic tissue was cut into 1-mm' pieces and placed
under the renal capsule using fine forceps. 5-0 sutures were used
to approximate the peritoneal layers, andmichel clips were placed
to close thewound. Allsurgical procedures were performedunder
sterile conditions in a laminar flow hood.
After 1-3 mo, mouse thymus, spleen, liver, and kidney with
human xenograft were removed, snap frozen in a dry ice/ethanol
slurry, and stored in liquid nitrogen. Mouseperipheral blood (PB)'
was processed for surface staining of mononuclear cells using
anti-human andanti-mouse mAbreagents andanalyzed on aFACS
Star Plus (Becton Dickinson & Co., Mountain View, CA).
Immunosuppressive Treatment ofSCID Mice.
￿
Animalsengrafted
with human postnatal thymic tissue received either no treatment,
pretreatment (1-5 dbefore engraftment) with sublethal wholebody
ti irradiation (400 cGy) (11), or received long-termintraperitoneal
administration (every 4-5 d after graft placement) of 25 1Al of
'Abbreviations used in this paper: DP, double positive;E, eosin; GAM, goat
anti-mouse; H, hematoxylin; Hh-1, hematopoietic histocompatibility 1;
hpf, high-powered field; IF, immunofluorescence; PB, peripheral blood;
poly I/polyC, polyinosinic-polycytidyhc acid; SP, singlepositive;TE, thymic
epithelium.
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anti-asialo GM-1 (Wako, Richmond, VA), arabbit antiserumagainst
murine NK cells and macrophages (12, 13). Using indirect im-
munofluorescence (IF) assays on human thymus tissue or human
thymocytes in suspension, we found anti-asialo GM-1 serum did
notreactwith human thymocytes. Moreover, NK activity in SCID
mice pretreated with the IFN inducer, polyinosinic-polycytidylic
acid (poly I/poly C) (as measured by "Cr release assay against
YAC-1 target cells), was reduced by 92% 4 d after a single injec-
tion of anti-asialo GM-1 as compared with control SCID mice in-
jected with normal rabbit serum.
Antibodies.
￿
Thefollowinganti-human mAbs were used: CD1a
(NA1/34; from A. McMichael, Oxford University) (14), CD3
(Leu4; from R. Evans, RoswellPark Memorial Institute, Buffalo,
NY) (15), CD4 (T4/19, Thy-5D7; from E. Reinherz, Harvard
University), CD8 (OKT8; American Type Culture Collection,
Rockville, MD), CD7 (3A1aand3A1e)(16),CD45 (F10-89-4) (17)
and CD45RA (F8-11-13) from R. Dalchau andJ. Fabre, Oxford
University) (18), CD45RO (UCHIrl; from P. Beverley, Univer-
sity College, London) (19), fibronectin (FN-15; Sigma Chemical
Co., St. Louis, MO), CD44 (AIG3) (20), CD29 (VLAO, K20;
from A. Bernard, Nice, France) (21),anti-HLAA2 (MAS 2.1; from
M. McCune, Systemix, Inc., Palo Alto, CA) (8), anti-HLA class
Imonomorphic(3F10) (22), anti-HLA class II DR monomorphic
(L243) (23), anti-HLA antibodies against polymorphic HLA de-
terminants 88.2 (DR5), DR7M (DR7), JS-1 (DR3), GS359-13F10
(DR4), 295-3115 (DQ3) 4AA7 (DQI+4), 296-8F9 (DQ mono-
morphic), 8.1 (B8), 295-8D8 (B5), 145.2 (B27), 20.1 (A2, Aw69)
and 192.1(A9, A32134) (allfrom S. Radka, GeneticSystems, Seattle,
WA), V2 (anti-human vessels), A2B5 (anti-GQ ganglioside/ an-
timedullary thymic epithelium [TE]) (24),TE4(antimedullary TE)
(25), TE7 (anti-human fibroblasts) (25), TE3 (anti-human cor-
tical TE and fibroblast) (26), TE8 (anti-human Hassall's bodies)
(27), TCR-61 (antiTCRS, M. Brenner, HarvardUniversity) (28),
0F1 (antiTCR-0; M. Brenner) (29), AE-3 (anti-human keratin;
from H. Sun, NYU, New York) and 12/1-2 (anti-HTLV-1 p19)
reactive with subcapsular cortical and medullary TE cells (30).
Antibodies against mousemoleculesincluded antiTCRf3 (H57-
597; R. Kubo, NationalJewish Hospital, Denver, CO) (31), CD4
(L3T4; Becton Dickinson & Co.), CD8 (YTS169.4; Sera Labs,
Sussex, UK), Thy-1 (NIMR-1; Sera Labs), mouse macrophages
(MI/70.15; Sera Labs), mouse NK cells(SW5E6; V Kumar, South-
western Medical Center, Dallas, TX) (32), andmouse CD3e (145-
2C11; J. Bluestone, University of Chicago, Chicago, IL) (33) . Each
antibody wasused at an optimal saturating concentrationas deter-
minedfrom titrationexperiments. Controlantibodies included ei-
ther irrelevant mousemAbs, P3 x 63/Ag8 ascites, or directly la-
beled murine myeloma paraproteins.
Immunohistologic Staining of Mouse Tissues.
￿
Tissue specimens
were embedded in OCTcompound (Lab Tek Products, Naperville,
IL), cut into 4-,um sections, and fixed in acetone (-40°C) for 5
min. Hematoxylin (H)andeosin(E)stains were performedon tissue
sections of engrafted kidneys every 120 gm. Tissue sections were
used immediately for immunohistologic staining or were stored
at -70°C.
Anti-human mouse mAbs were either directly fluoresceinated
or used in indirect IF assay with FITC goat anti-mouse IgG(GAM-
FITC) (Kirkegaard &PerryLaboratories, Inc., Gathersburg, MD).
Anti-mouse mAbs were either directly fluoresceinated or used in
indirect IF assays with mouse anti-rat Ig FITC, (0X12-FITC; Sera
Labs). Direct andindirect IF wasperformedon acetone-fixed, 4-pm
tissue sections as previously described (34). For determination of
therelative proportions ofhuman immune cells present in thymic
xenografts, thenumber of CD7, CD3, CD4, CD8, CD1. TCR-0,(OF1), andTCR-S (TCR61) -positive cells were visually counted
using indirect IF and expressed as an estimated percent (to nearest
5%) of human CD45* cellspresent (35). For determination of the
relative proportions of murine immune cells present in human
thymic xenografts and in mouselymphoid organs, the number of
TCR,fl, CD3, CD4, andCD8-positivecellswere visually counted
using indirect IF and expressedas an estimatedpercent (to nearest
10%) of murine Thy-1` cells present (35).
ELISA for Quantitation of SCID Mouse Ig Levels.
￿
A two-site
ELISAwasused to determineserumlevels of murine IgMand IgG.
Briefly, goat anti-mouse F(ab')2 fragments (anti-F[ab']2 fragment
specific) were coated onto high-bind EIA microtiter wells(Costar,
Cambridge, MA) (2 h, 25 °C). Theplates were blocked with 3%
BSA (1 h, 25°C) and washed three times with 0.05% Tween 20
in PBS. Twofold dilutions of SCID mouse sera samples were
incubated in microtiter wells (1 h, 25°C). After washing, alka-
line phosphatase-conjugated anti-mouse IgM (t~ specific) (Fisher
Scientific Co., Pittsburgh, PA)or anti-mouse IgG(-yspecific) (Fisher
Scientific Co.) wasadded(1:1,000 dilution) (1 h, 25°C). Theamount
of mouse IgM or IgG bound was measured by hydrolysis of
paranitrophenylphosphate (Sigma Chemical Co.) at 405 nm in an
Anthros 2001 ELISAreader (Denley Instruments, Durham, NC).
IgM and IgG antibody concentrations forSCID mice were calcu-
latedby linear regression analysis from astandard curvegenerated
usingpurified myelomaproteins of known concentrations: TEPC
183 (IgM, a) (Sigma Chemical Co.) or MOPC 195 (IgG2b, rc)
(Litton Bionetics, Kensington, MD). Mice were determined to be
"leaky" (SCID[Igi]) if murine serum IgM and IgG levels were
>50 ttg/ml (9, 36). Alternatively, in preliminary studies, we also
found that reaction of GAM-FITC with SCID mouse tissue was
an indicator of SCID(Ig') status, and the reactivity of GAM-
FITC with mouse kidney was used to indicate SCID(Ig') status
in select animals in whom serum was not available.
Results
Engraftment of Human Postnatal Thymus in SCID Mice
Table 1 shows the effect of irradiation and anti-asialo GM-1
treatment on the rate of engraftment of human postnatal
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Table 1.
￿
Human Postnatal Thymic Xenograft Survival in
SCID Mice after No Treatment, Treatment with 400 cGy Whole
body y Irradiation, or Anti-asialo GM-1 Treatment
No. No. Percent
Treatment
￿
operated engrafted" engraftment
No treatment
￿
43
￿
16
￿
73%
400 cGy gamma irradiation
￿
18
￿
15
￿
83%
Anti-asialo GM-1
￿
23
￿
16
￿
70%
Total
￿
84 47 56%
" Engraftment of human postnatal thymic tissue was defined as visible
human thymic tissue present at thetime of autopsy that was confirmed
as humanin origin by immunohistologic staining usinganti-human mAbs.
thymus in SCID mice. Of 84 total mice operated, 47 viable
grafts were present after 1-3 mo (56%). 43 untreated SCID
animals had human thymic tissue implanted, and after 1-3
mo, 16 (37%) hadviable thymus grafts present. In contrast,
pretreatment ofSCID mice with either sublethalwholebody
y irradiation (400 cGy) or treatment with anti-asialo GM-1
improved human thymic graft survival to 83 and 70%, respec-
tively.
Theaverageleukocytecounts in engrafteduntreated SCID
mice were similar to leukocyte counts previously reported
in nongrafted SCID mice (37) (Table 2). Both sublethal ir-
radiation ofSCID mice and treatmentwith anti-asialo GM-1
significantly lowered the lymphocyte count at the time of
graft harvest (p < 0.005 and 0.02, respectively). However,
only treatment with anti-asialo GM-1 lowered thePB mono-
cyte count (p < 0.001). When PB mononuclear cells were
analyzed for a subset of NK cells as defined by mAbSW5E6
(33), we found that both irradiation and anti-asialo GM-1
At the time of autopsy (1-3 mo after implantation of human thymus tissue), mice were bled retroorbitally. Differential counts were performed on
Wright-stained PB smears, and total leukocyte counts were determined on a cell counter (Coulter Immunology). Results are expressed as mean
number of PB cells per mm3 t SEM.
' Indirect IF and flow cytometry analysis using NK cell marker SW5E6 was also performed on a subset of mice within each treatment group. PB
was taken 4-5 d after injection with anti-asialo GM-1 antisera. For number of SW5E6 4 NK cells, n = 9foruntreatedgroup, n = 8 forirradiation
group, and n = 11 for anti-asialo GM-1 group.
t Significantly different from untreated group (p < 0.005).
S Not significantly different from untreated group (p < 0.7).
II Significantly different from untreated group (p < 0.01).
1Significantly different from untreated group (p < 0.02).
'* Significantly different from untreated group (p < 0.001).
Table 2. PBL Counts in SCID Mice Engrafted with Human Thymus after Various Treatment Regimens
Treatment
No. of
mice tested Leukocytes
mm3
Neutrophils
mm3
Lymphocytes
mm3
Monocytes
mm3
SW5E6' NK
cells"
mm3
No treatment 46 2,576 ± 258 1,643 t 186 853 ± 83 79 ± 17 167 ± 41
400 cGy y irradiation 15 2,014 f 400 1,685.± 325 419 ± 118# 146 ± 70S 28 ± 151
Anti-asialo GM-1 24 2,074 ± 441 2,120 ± 370 567 ± 961 16 ± 6"' 34 ± 20ttreatment significantly decreased the number of SCID PB
SW5E6+ NK cells by 83 and 80%, respectively .
We next determined ifhuman leukocytes couldbe detected
inmouse PB at the time of autopsy after 1-2 mo ofengraft-
ment . Using two-color flow cytometry with directly con-
jugated CD7-FITC and CD45-PE reagents, rare CD45+,
CD7 - cells (69 ± 7 cells/mm3) were present in PB in en-
grafted SCID mice in the untreated, engrafted group (n =
3) . No circulating human CD45+ cells could be found in
engrafted SCID mice treated with either irradiation (n =
T" 3 .
￿
Characterization of Human Postnatal Thymic Grafts Placed in Untreated SCID Mice
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Figure 1. Gross and histologic morphology of
human postnatal thymic grafts implanted under the
renal capsule ofSCID mice. (A)Amacroscopic view
of thymic xenograft 11-6 (3 x 2mm), 6wk after place-
ment under the renal capsule. (B) Low-power view
of graft 11-6 under the renal capsule (c) . The human
thymic graft is outlined by black arrows . The dotted
line indicates the graft-kidney interface. (C)Athymic
xenograft (2 x 2mm), 10wk after placement under
the renal capsule ofSCID mouse 14-2 . (D) Low-power
view ofgraft 14-2 documents the histology of the graft
underneath the renal capsule (c) . Dotted line points
out graft-kidney interface. Solid white bar inA and
C - 1 mm (B and D, x100 ; H and E stain) .
13) or anti-asialo GM-1 (n = 12) . Immunohistologic anal-
ysis ofSCID mouse spleen and mediastinal thymus from un-
treated animals engrafted with human thymus showed no
detectable CD7+ or CD3+ human cells in these mouse
organs (data not shown) .
All human thymus tissue used as xenografts were screened
in indirect IF assays on tissue sections for reactivity with mono-
morphic and polymorphic HLA class I and class 11 mAbs
before and following engraftment . Monomorphic and poly-
morphic HLA class II mAbs reacted with only human TE
Numbers represent estimated percent of cells positive relative to the number of CD45' cells, with the number of CD45 cells at 100% . Rare, one
to two cells positive per slide. + , cells present reactive with mAb in IF assays . -, no cells present reactive with mAb in IF assays . Similar data
were obtained in an additional five grafts in untreated SCID mice (data not shown) .
Graft
No .
Days after
engraftment
Thymic
Keratin
epithelium
TE4 TE3
Fibroblast
(TE7)
Vessels
(V2)
Macro-
phages
(Leu-M3) CD45 CD7 CD3
Human
CD4
thymocytes
CD8 CDI TCR-# TCR-6
2-2 30 + + + + + 100 100 100 80 100 100 ND 0
2-5 46 + - + + + 100 30 20 15 Rare 0 Rare Rare
3-1 45 + + + + + 100 100 100 100 100 0 100 Rare
6-3 51 + + + + ND ND Rare 0 0 0 0 0 0 0
6-9 55 + - + + + 100 10 ND 30 0 0 15 0
3-8 57 + + + + + 100 100 100 80 80 Rare 100 Rarecells and macrophages in thymic grafts while HLA mono-
morphic and polymorphic HLA class I mAbs reacted with
human TE cells, fibroblasts, and vessels. In 18 grafts tested
among all treatment groups, polymorphic HLA antigens ex-
pressed by the thymic graft were identical to the polymorphic
HLA antigens expressed by the thymic tissuebefore engraft-
ment (data not shown) .
Fig. 1 shows the gross and histologic morphology ofrep-
resentative mouse kidneys (nos . 11-6 and 14-2) bearing 6- and
10-wkhuman thymic grafts. After 1-2 mo, thehuman grafts
routinely increased in size by threefold. However, when the
human thymic grafts from each treatment regimen were tested
for the presence ofhuman thymic microenvironment com-
ponents and for thymocyte subsets, we found the xenografts
in each treatment group were dramatically different .
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Characterization ofHuman Thymic Grafts in Untreated SCID
Mice. After 1-2 mo of engraftment, grafts in the untreated
SCID mouse group contained both human thymic microen-
vironment components and varying numbers ofhuman thymo-
cytes (Table 3) . Immunohistologic analysis of representative
graft 2-2 (Fig. 2) shows thepresence ofhuman thymic microen-
vironment components, including human fibroblasts and
keratin-positive thymic epithelium as defined by anti-human
fibroblast marker, TE7 (Fig. 2 B), anti-human keratin anti-
body, AE-3 (Fig . 2 C), and by the medullary TE cell marker,
TE4 (Fig. 2 D) . Of 10 grafts studied using immunohisto-
logic techniques, all had TE7+ thymic fibroblasts present .
Moreover, in 9 of 10 grafts, TE7+ cells invaded the renal pa-
renchyma to a depth of 100-400 j.M (Fig . 2 B) . 3 of 10 grafts
in untreated mice had only TE7+ fibroblasts present with
Figure 2 .
￿
Phenotypic analysis using indirect IF assays
of a human postnatal thymic xenograft, 4 wk after
implantation under the renal capsule of SCID mouse
2-2 . (A)H and E stain of graft no. 2-2 ; L indicates
Iymphoid area, dotted line outlines border of graft,
rt points out renal tubules. (B) TE7+ thymic fibro-
blasts surrounding a TE7- lymphoid area (L); TE7+
cells are seen invading the renal parenchyma and sur-
rounding renal tubules (a). (C) Keratin-positivethymic
epithelium using anti-human keratin antibodyAE-3 ;
arrows point to AE-3+ TE cells . (D) Medullary thy-
mic epithelium as identified by TE4, an antimedul-
lary TE cell marker (x400) .no AE-3/TE4+ TE cells present, while the remaining seven
grafts in this group also contained keratin-positive TE cells .
As seen in Figs. 1, B and D, and 2 A, human postnatal
thymic grafts in SCID mice lost their normal morphology
and assumed a dysplastic morphology, with only rare Has-
sall's bodies present . None ofthe thymic grafts studied using
indirect IF assay had a definable cortico-medullary junction .
In grafts that contained TE cells, TE cells formed islands of
keratin-positive, TE4+, A2B5+, p19+ thymic epithelium,
suggesting that the predominant epithelial cell type was medul-
lary and subcapsular cortical thymic epithelium (24-26, 30) .
In all but two grafts tested, the TE4+ medullary epithelium
was also TE3+ (Fig . 3) . In normal thymus, TE4+ medul-
lary and subcapsular cortical thymic epithelium is mutually
exclusive of TE3+ cortical epithelium, except for a minor
subset of TE3+, TE4+, normal TE cells in the subcapsular
cortical area (26) . TO is also normally expressed intracellu-
larly in thymic fibroblasts and macrophages (26, 38) . Thus,
in postnatal thymus grafts in SCID mice, thymic epithelium
was not normal and expressed bothTE4 and TE3, a pheno-
type identical to that seen only in a rare subset of normal
subcapsular cortical TE cells (26) .
Human vessels were present throughout thymic grafts in
the untreated SCID mouse group, and varied in size from
small capillaries to large muscular arteries. As with TE7+
cells, V2+ endothelial cells routinely invaded the underlying
renal parenchyma . In two to five grafts tested, human vessels
were positive for human fibronectin, LFA-3, ICAM-1, and
VLA /3 (data not shown) (reviewed in references 1, 39, and 40) .
In untreated SCID mice with human thymic grafts, the
human lymphoid component of the thymic graft varied in
number and in phenotype. Table 3 shows an analysis of six
human grafts present in untreated SCID mice. Human lym-
phoid cells present in untreated SCID mice were either
CD4+, CD8+, CD1+ cells (graft 2-2) (Fig . 4), CD4+,
CD8+, CD1 - cells (grafts 3-1 and 3-8), or of less mature
phenotypes (grafts 6-3 and 6-9) . When reacted with either
OR (antiTCR/3) and TCR-S1 (antiTCR-S), most thymo-
cytes wereTCRa+ (grafts 3-1 and 3-8) with only rare (one
to two cells positive per slide) TCR-S+ cells present . In
grafts 6-3 and 6-9, most of the CD45+ cells present were
bothTCR-0 - and TCR-S - (Table 3) . In three grafts (9-4,
9-5, and 9-13), only TE7+ fibroblasts were present without
either CD45+ human lymphoid cells or keratin-positive TE
cells (data not shown) .
Fig . 4 shows the lymphoid component of a 4-wk human
postnatal thymic graft (no . 2-2) in an untreated, engrafted
SCID mouse. Fig. 4, B-F, shows human thymocytes in the
graft stained with human T cell lineage markers CD7, CD4,
CD8, CD3, andCD1 ; most thymocytes present in graft 2-2
reacted with all ofthese antibodies . Interestingly, in untreated
SCID mice, using antibody Leu-M3 as a human macrophage
marker, we found only rare Leu-M3+ cells (Table 3) . Using
mAbs specific for mouse T cells (CD3E, Thy-1), we found
that 50% of grafts in this group contained rare (1-3
cells/section) murine T cells . Finally, of the untreated mice
with viable human thymic grafts, none were found to beSCID
(Ig+) at the time of graft harvest .
Characterization ofHuman Postnatal Thymus Grafts inSCID
Mice Pretreated with 400 cGyy Irradiation . In contrast to un-
treated SCID mice, when animals were treated with 400cGy
y irradiation before engraftment, the resulting grafts were
comprised primarily of thymic microenvironment compo-
nents only, and were markedly depleted ofhuman or murine
T cells in seven of nine grafts tested . Table 4 summarizes the
characterization of nine thymus grafts studied from animals
that had been irradiated before engraftment . In contrast to
human thymus grafts in untreated SCID mice, Leu-M3+
macrophages were observed in irradiated SCID mice in seven
of nine thymus grafts and were present in large numbers (>20
Figure 3.
￿
Phenotypic analysis using indirect IF assays of human thymic epithelium in a human xenograft placed under the renal capsule of SCID
mouse 3-8 . Figure 'shows sequential 4-)Am frozen sections of the same island of thymic epithelium in the thymic xenograft from SCID mouse 3,-8 .
(A) TE cells are keratin positive, as determined by reactivity with mAb AE-3 . Moreover, the same TE cells also areTO + (B), and TE4+ (C) (x400) .
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Figure 4 .
￿
Phenotypic analysis using
indirect IF assays ofa human postnatal
thymic xenograft, 4wk after implan-
tation under the renal capsule ofSCID
mouse 2-2 . (A) H and E stain of graft
2.2 ; arrows point out thymocyte ag-
gregates, dotted line delineates border
of graft, c indicates renal capsule, rt
indicates renal tubules. Phenotypic
analysis of human thymocytes as
defined by CD7 (B), CD4-(C), CD8
(D), CD3 (E), and CD1 (F) . Dark
area under renal capsule in E is space
between the graft andthe capsule and
not CD3- human T cells (B, C, D,
E, and F, x400 ; A, x100) .
Figure 5 .
￿
Phenotypic characterization using indirect
IF assays ofhuman thymic graft in SCID mouse 13-1 ir-
radiated with 400 cGy before engraftment . (A) Human
fibroblasts present, reactive with antibody TE3. Fibro-
blasts are seeninvading the mouse kidneybelow thegraft-
kidney interface (dotted line) . (B) Keratin-positive human
thymic epithelium, as identified bymAb AE-3, is present
in graft (area above dotted line). (C) CD45' human
thymic macrophages, also found to be Leu-M3 and
Mo-1 *, were present throughout the graft . (D) V2 reac-
tivity with human vessels (v) and endothelial cells (arrows).
V2' endothelial cells invaded the renal parenchyma be-
yond the graft-kidney interface (dotted line) (x400).cells/high-powered field [hpl) in five grafts. Fig. 5 shows
a representative human thymus graft (no. 13-1) in theirradi-
ation treatment group. Graft 13-1 contained human fibro-
blasts (Fig. 5 A), keratin-positive human thymic epithelium
(Fig. 5 B), numerous human thymic macrophages (Fig. 5C),
and V2+ endothelial cells (Fig. 5 D). Human V2+ endo-
thelial cells routinely invaded the murine renal parenchyma
(Fig, 5 D), as did TE7+ human fibroblasts (data not shown).
Only two of nine animals studied in this group had clusters
of CD45+, CD3+ human T cells present in thymus grafts.
Most of theT cells present in graft 8-11 were CD4-, CD8-,
TCR-(3+ cells, while CD1+, CD4', CD8+, TCR(3+ cells
predominated in graft 8-14 (Table 4). Otherwise, only thymic
microenvironment components predominated in human
thymic grafts in irradiated animals. As with the untreated
Table 4.
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SCID group, either no or rare murine T cells were present
in humanthymic grafts placed in irradiated SCID recipients.
In addition, no irradiated mice with viable humanxenografts
were found to be SCID(Ig+) at the time of graft harvest.
Characterization ofHumanPostnatalThymus Grafts in SCID
Mice Treated With Anti-asialo GM-1. To furtherfacilitate en-
graftment of human thymic tissue, we treated SCID animals
with anti-asialo GM-1 antiserum to decrease NK cell and
monocyte/macrophage number andfunction (12, 13). Of 23
grafts implantedin this group, 16 (70%)human thymic grafts
survived andgrew. Surprisingly, at 1-2mo after engraftment,
of 16 animals with viable thymus grafts, six (38%) had be-
come SCID(Ig+).
In anti-asialo GM-1-treated animals that were SCID(Ig-)
at autopsy, thymus grafts were similar to grafts in untreated
Numbers represent estimated percent of cells positive relative to the number of CD45* cells present, with the number of CD45 cells at 100%.
Rare, 5-10 cells/slide. +, cells present reactive with mAb in IF assay. -, no cells present reactive with mAb in IF assay. LC, rare CDl+ dendritic
cell present consistent wih Langerhan's cells. NA, not applicable sincemacrophages were CD4+ and therefore rare thymocytes could not be evaluated,
Table 5.
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Characterization of Human Postnatal Thymic Grafts in Anti-asialo GM-1 Antiserum-treated SCID (Ig -) Mice
Numbersrepresent estimated percent of cells positive relative to the number of CD45+ cells, with the number of CD45 cells at 100% . Rare, 5-10
cells/slide. +, cells present reactive with mAb in IF assay. -, no cells present reactive with mAbin IF assay. NA, not applicable sincemacrophages
were CD4+ and therefore rare thymocytes could not be evaluated.
' For 11-7, TE cells were p19+, another marker of medullary TE cells (29).
Graft
No.
Days After
engraftment
Thymic
Keratin
epithelium
TE4 TE3
Fibroblast
(TE7)
Vessels
(V2)
Macro-
phages
(Leu-M3) CD45
Human
CD7 CD3 CD4
thymocytes
CD8 CD1 TCR-R TCR-S
13-1 30 + + + + + Rare Rare Rare NA Rare LC Rare 0
13-2 30 + + + + + Rare Rare Rare Rare Rare LC Rare 0
13-4 30 + + + + + Rare Rare Rare NA Rare 0 Rare 0
13-5 30 + + + + + Rare Rare Rare Rare Rare 0 Rare 0
8-5 30 + + + + + Rare 0 Rare NA 0 0 0 0
8-6 30 + + - + + Rare 0 0 NA 0 0 0 0
8-11 30 + + + + + 100 Rare Rare NA Rare Rare 100 0
8-12 30 + + + + - 0 0 0 0 0 0 0 0
8-14 30 + + + + + Rare 100 80 50 80 80 80 50 0
Graft
No.
Days after
engraftment
Thymic
Keratin
epithelium
TE4 TE3
Fibroblast
(TE7)
Vessels
(V2)
Macro-
phages
(Leu-M3) CD45 CD7
Human
CD3 CD4
thymocytes
CD8 CD1 TCR-(3 TCR-S
11-2 30 + + + + + Rare 100 0 15 15 50 0 30 0
11-3 30 - - - + + - 0 0 0 0 0 0 0 0
11-4 30 + - + + + - 100 0 30 0 0 0 0 0
11-5 30 + + + + + - 100 10 100 10 0 50 50 20
11-6 43 + + + + + Rare 100 100 100 100 40 20 100 0
11-7 43 + + + + + Rare Rare Rare Rare NA 0 0 Rare 0
14-7 89 + +* + + + Rare 100 50 100 50 0 0 50 0Table 6.
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animals, with thymic microenvironment components with
varying numbers of thymocytes, and only rare Leu-M3+
macrophages present (Table 5) .
In five of six anti-asialo GM-1-treated mice that were
SCID(Ig+) at the time of graft harvest, large lymphoid
grafts were present under the renal capsule (Fig . 1, C and
D) . However, in striking contrast to anti-asialo GM-1-treated
SCID(Ig - ) mice, none of the lymphoid cells in human
thymic grafts in SCID(Ig+) anti-asialo GM-1-treated mice
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For murine T cells, numbers represent the estimated percent of cells positive relative to the number of Thy-1 * cells, with the number of Thy-1 +
cells at 100%n . Rare, 5-10 cells/slide . +, cells present reactive with mAb in IF assay . -, no cells present reactive with mAb in IF assay .
were human T cells . Rather, 100% of the lymphoid cells
colonizing human thymic microenvironment components
were murine CD3e+, TCR-(3+ SCID T cells (Table 6, Fig.
6) . In direct IF assays, thechimeric thymus grafts contained
murine T cells that varied in phenotype from all CD4+
single-positive (SP) cells (no . 10-6) to mixtures of CD4+
and CD8+ cells (nos. 10-7, 14-2, and 14-9) (Table 6) . In
double staining experiments on grafts from animals 14-2 and
14-9, the expression of murine CD4 and CD8 was found
Figure 6.
￿
Phenotypic characterization using direct IF
assays ofhuman-mouse chimeric thymic graft in anti-asialo
GM-1-treated SCID(Ig+) mouse 14-2 after engraftment
with human postnatal thymus. (A) HLA A2+ human
thymic epithelium, as defined by reactivity with mAb
MA2.1, (anti-HLA A2).Acentral human Hassall's body
(HB) was present . (B) All lymphoid cells present in graft
14-2 were murine CD3e+ using mAb 145-2C11, while
(C) none ofthe lymphoid cells present in graft 14-2 were
reactive with the anti-human CD45 antibody, F-10-
89-4 . (D) The majority the murine CD3e+ lymphoid
cells present in the graft 14-2 were TCR-/3+, using the
anti-murine TCR-fl mAb, H57-597. Dotted line in all
panels indicates the graft-kidney interface (x400) .
Graft
No .
Days after
engraftment
Thymic
Keratin
epithelium
TE4 TE3
Fibroblast
(TE7)
Vessels Macrophages
(V2) (Leu-M3)
Human
thymocytes
(CD45) CD3
Murine
TCR-O
thymocytes
CD4 CD8 Thy-1
10-6 65 + + ND + ND 0 100 100 100 Rare 100
10-7 82 + + ND + + Rare 100 100 60 40 100
11-9 71 - - - + ND 0 Rare Rare 0 0 Rare
11-10 71 + ND ND + - 0 100 10 20 0 100
14-2 89 + + ND + - 0 100 100 80 20 100
14-9 89 + + ND + + 0 100 100 80 20 100to be mutually exclusive in the majority of mouse lympho-
cytes (ti90%), although these techniques couldnot rule out
the presence of a small proportion of CD4+, CD8+ double-
positive (DP) cells. Murine TCR-/3+ T cells were present in
and around humanthymic epithelium, and as well were scat-
tered throughout TE7+ human thymic fibroblasts. TE7+
cells invaded the renal parenchyma, 100-400 /.M, and mu-
rine T cells were scattered in interstitial areas of the mouse
kidney in asimilar zone around the humangraft. In thekidney
interstitium, mouse T cells were frequently in close prox-
imity to human TE7+ cells (data not shown).
Determination of the Effects of Anti-asialo GM-1 Treatment
on Induction ofSCID(Ig+) Status in SCID Mice. In our ini-
tial setof experiments, we foundthat 38% of anti-asialo GM-
1-treated mice with thymus xenografts became SCID(Ig+)
2-3 mo after engraftment, as compared with 0% of mice
in the untreated and irradiated groups. To clarify the factors
responsible for induction of SCID(Ig+) status, age-matched
SCID(Ig+) mice were treated with either anti-asialo GM-1
alone, anti-asialo GM-1 plus engraftment, or normal rabbit
serum (50 1.1, i.p.), and the presence of serum mouse Ig was
determined after 60 d. Of nine SCID(Ig-) mice treated with
normal rabbit serum every 4 d, none became SCID(Ig+)
after 2 mo. However, in 10 SCID(Ig-) mice treated with
anti-asialo GM-1 every 4 d but not engrafted, four (40%)
became SCID(Ig+) after 2 mo. Moreover, of an additional
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35 anti-asialo GM-1-treated, engrafted animals, 14 (40%)
became SCID(Ig+) after 2 mo. Taken together, these data
demonstrate that long-termintraperitoneal administration of
anti-asialo GM-1 antiserum alone led to induction of SCID
(Ig+) status in -40% of SCID mice, suggesting a role for
NK cell- and/or monocyte-mediated suppression of lym-
phopoiesis in these animals.
Phenotype ofMurine T Lineage Cells in SCID Mouse Lym-
phoid Tissues in Various Groups ofSCID Mice. We next evalu-
ated mouselymphoid cells present in mouse spleen and thymus
of SCID mice in all three treatment groups (Table 7). First,
as normal controls, three age-matched (161 d), untreated,
nonengrafted SCID mice were screened for mature mouse
T cells in spleen and thymus. As reported previously, SCID
(Ig-) mouse thymus contained Thy-1+, cCD3+, TCR-0-
cells with rare CD4+, CD8+ cells present (42). In one age-
matched SCID(Ig+) animal (no. 26-2), rare splenic TCRa+
cellswere detected. Similarly, untreated SCID mice (134-177
d) that were engrafted for 30-57 d contained only rare
CD4+ or CD8+ cells in spleen and thymus. Anti-asialo
GM-1-treated and engrafted mice (113-175 d; engrafted for
30-89 d) that remained SCID(Ig-) at the time of autopsy
had clusters of CD4+ and CD8+ thymocytes present in two
of three animals, with rare CD4+ or CD8+ cells present as
well in the spleen. In contrast, anti-asialo GM-1-treated mice
(154-162 d; engrafted for 71-89 d) that became SCID(Ig+)
Phenotypic analysis performed as in Table 6.
Rare is one to five positive cells per three to five in hpf. +, large clusters of positive cells (>10 cells/hpf) present around splenic arterioles. -, no
cells positive.
In nongrafted control SCID mice, no human thymic grafts were implanted.
t 26-2 was SCID(Ig') at time of study.
Table 7. Phenotypic Analysis of Murine T Lineage Cells in Mouse
Mouse thymus
Mouse SCID
type Mouse CD3 CD4 CD8
Lymphoid
TCR-/3
Tissues from SCID
CD3
Mice in Various Treatment
Mouse spleen
CD4 CD8
Groups
TCR-Q
Nonengrafted, untreated SCID mice'
26-1 80 Rare Rare 0 - Rare Rare -
26-2t 80 Rare Rare 0 Rare Rare Rare Raret
26-3 80 Rare Rare 0 - Rare Rare -
Engrafted, untreated SCID mice
2-2 90 Rare 0 0 Rare Rare Rare
3-8 80 Rare 0 Rare - + -
6-9 ND Rare 0 Rare - + -
Engrafted, anti-asialo GM-1-treated, SCID(Ig-) mice
11-2 90 80 90 Rare - Rare Rare
11-6 80 0 0 0 - - -
14-7 80 80 80 Rare - + Rare
Engrafted, anti-asialo GM-1-treated, SCID(Ig`) mice
14-2 100 50 50 10 + + + +
14-9 80 80 80 10 + + + +
11-10 100 50 90 0 + + + -had large clusters of murine TCR-,3+ cells in mediastinal
thymus and in spleen in two of three animals tested (nos.
14-2 and 14-9). Moreover, large numbers (10-50 cells/hpf)
of CD4+ and/or CD8+ cells in thymus and spleen were
present in all three anti-asialo GM-1-treated animals that be-
came SCID(Ig+) . One such animal (no. 11-10) had large
numbers of CD4+ and/or CD8+ cells in thymus and spleen,
but no TCR-O+ cells present. Interestingly, this animal also
had subsets of murine cCD3+, CD4 - , CD8 - , TCR-0-
and cCD3+, CD4+, CD8 - , TCR-0 - cells in the human
thymus graft, documenting in this animal the homing ofim-
mature SCID mouse T cells to the human thymic xenograft
(Table 6).
Discussion
In this study, we have shown that human postnatal thymic
tissue will grow as xenografts in SCID mice. The compo-
nentsof the human thymic grafts at 1-3 mo varied with the
immunosuppressive regimen used in the SCID mouse recip-
ient. Xenografts from untreated SCID mice contained both
human thymic microenvironment and thymocytes, whereas
irradiation ofSCID mice before engraftment yielded primarily
human thymic microenvironment grafts containing human
macrophages but devoid of human or murine thymocytes.
Treatment of SCID mice with anti-asialo GM-1 after en-
graftment resulted in murine B cell antibody production
(SCID[Ig+]) in 38% of animals. Remarkably, in five of
the six SCID(Ig+) mice, the human thymic grafts grew
well, were highly lymphoid, but in contrast to untreated and
irradiated SCID recipients, contained exclusively murine
TCR-a+ T cells.
Mice homozygous for the SCID mutation exhibit markedly
impaired lymphopoiesis, while myelopoiesis is unaffected (10,
43). Despite this selective deficiency, SCID mice have normal
levels of NK cells and NK cell precursors and show levels
of NK cell activity similar to their C.B-17 counterparts
(44-46) . While in vivo treatment with anti-asialo GM-1 an-
tiserum has been used in several mouse strains to abrogate
NK activity, its use in SCID mice to enhance engraftment
of human tissue has not been reported.
The observation that anti-asialo GM-1 treatment alone in-
duced -40% of SCID mice to become SCID(Ig+) was a
striking finding in our study and may provide insights into
cellular controls ofthe recombinase defect in SCID mice (47,
48). Induction of both T and B cell lymphopoiesis by
anti-asialo GM-1 antiserum raises the notion that there may
be a cell-mediated suppression ofB and T cell lymphopoiesis
involving NK cells, macrophages, or both cell types in SCID
mice. For example, SCID NK cells and/or monocytes could
act by eliminating or suppressing the function ofcells respon-
sible for the production of cytokines necessary for induction
of recombinase in SCID T and B cell precursors (reviewed
in reference 49). Alternatively, SCID NK cells could sup-
press SCID lymphopoiesis by selective NK-mediated killing
ofautologousSCID lymphoid precursors. Murphy et al. (50)
have recently demonstrated in the setting of bone marrow
transplantation in SCID mice that NK cells can inhibit lym-
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phopoiesis, in that NK cells can mediate the rejection of T
cell-depleted bone marrow allografts. Murphy et al. (51) have
gone on to show that adoptively transferred SCID NK cells
can mediate hematopoietic histocompatibility 1 (Hh-1)-
mediated bone marrow rejection in vivo. Taken together with
the data in our current study, these observations raise the
hypothesis that SCID NK cells may mediate killing of autol-
ogous SCID lymphocyte precursors via the Hh-1 antigen
system.
In those anti-asialo GM-1-treated SCID(Ig+) animals in
which human thymus grafts were present, the grafts were
chimeric in that they contained human thymic microenviron-
ment components colonized exclusively by murine TCR/3+
T cells. The homing of murine TCR#+ T cells to the human
thymic microenvironment in SCID mice treated with anti-
asialo GM-1 could represent an attempt at thymus graft re-
jection, or alternatively, could represent maturation ofSCID
mouse T cell precursors in the human thymic microenviron-
ment. In mouse 11-10, the murine T cells were TCR-/3-
and were immature, demonstrating homing of immature
mouse T cells to the human xenograft at least in this one
animal. If the presence of murine T cells in human thymic
microenvironment grafts proves to represent colonization of
human thymic stroma with developing mouse thymocytes,
then this model system should be important for the determi-
nation of optimal methods for reconstitution of the human
T cell lineage across HLA barriers. Murine CTL precursors
have been reported to be positively selected during develop-
ment to recognize human HLA-A2 as a restricting element
in HLAA2 transgenic mice (52). In nude mice engrafted with
xenogenic rat thymus, chimeric grafts develop with mouse
T cell precursors colonizing the rat thymic microenviron-
ment (53). Moreover, we have recently shown human TE
cells can bind to SCID mouse thymocytes in vitro (Singer,
K.H., and B.F. Haynes, unpublished results). Thus, it is plau-
sible that developing mouse T cells could colonize a human
thymic microenvironment.
Human thymocytes were rare in grafts in anti-asialo GM-
1-treated SCID(Ig+) mice and in irradiated SCID mice. In
irradiated animals, the potential is present for vascular injury
to occur due to irradiation, predisposing thymocytes to die
out due to delayed vascularization. Moreover, although we
showed human thymocytes and thymic macrophages were
anti-asialo GM-1 negative in indirect IF assays, anti-asialo
GM-1 could react with human thymocytes or with macro-
phages at levels too low to detect in vitro in IF assays, yet
react at levels sufficient to result in thymocyte loss in vivo.
It is not clear why human/mouse chimeric grafts were seen
in anti-asialo GM-1-treated mice and not seen in irradiated
SCID mice. Total body sublethal y irradiation has been shown
to markedly reduce murine NK activity (54). 400 cGy of y
irradiation has been reported to be required for engraftment
of SCID mice with syngeneic bone marrow (9); this level
ofy irradiation has also been shown to damage SCID B lym-
phocyte precursors (11). Thus, it is likely that 400 cGy irradi-
ation damaged murine lymphoid precursors and prevented
murine T and B cell lymphopoiesis both in SCID hemato-poietic microenvironments and in the engrafted humanthymic
microenvironment.
The presence of numerous Leu-M3+ tissue macrophages
in thymic microenvironment grafts in irradiated SCID re-
cipients is intriguing and suggests that macrophage precursors
are present in human thymus that are capable of continu-
ously growing in irradiatedbut not in untreated or anti-asialo
GM-1-treated SCID mice (55, 56). In the Mosier et al. (57)
SCID mouse model, human monocytes did not engraft well,
while in the McCune et al. (8) model, engrafted human fetal
liver contained precursors of thymic dendritic cells that did
engraft.
In the present study, in all three groups of SCID mice,
there was a hierarchy of cell survival in human thymic grafts
placed, with fibroblasts and endothelial cells surviving longer
than TE cells, and TE cells surviving longer than thymo-
cytes. The paucity of thymocytes in several of the human
thymic grafts in untreated SCID mice couldindicate a limited
regenerating capacity ofpostnatal T cell precursor cells within
human thymus. In mice, reconstitution of bone marrow
chimeras with murine postnatal CD4 - ,CD8- ,CD3 - thymo-
cytes only transiently reconstituted mouse mature thymo-
cyte populations (58, 59). While we observed human thymic
grafts containing TE cells with no thymocytes, we did not
see human thymic grafts with thymocytes in the absence of
human TE cells. These data suggest dependence of thymo-
cytes on TE cells, and dependence of TE cells on fibroblasts
and endothelial cells to grow in vivo (reviewed in references
1 and 38) . Indeed, a role for fibroblast-produced cytokines
on human TE cell growth has been suggested to be impor-
tant in early thymic organogenesis (reviewed in reference 38) .
Finally, it is important to compare the system described
in the present report with the SCID-hu system of McCune
et al. (8). The simultaneous transplantation of human fetal
thymus and fetal liver by McCune et al. gave rise to thymic
grafts containing the thymic microenvironment from the
humandonor thymus and thymocytes and dendritic cells from
the fetal liver (8). Experiments were not reported on the fate
of human fetal thymus grafts placed in SCID mice alone,
although thymus grafts from donors >20 wk of gestational
age were reported to grow less well than grafts from earlier
tissues (8). Our study demonstrates that human postnatal
thymus tissue from children of 1-14 mo gestational age grow
in SCID mice and routinely increased in size by threefold
over a 60-d period. The size increase observed in our study
was less than that reported by McCune et al., perhaps for
two reasons: (a) none of our engrafted animals were simul-
taneously given a source of bone marrow or fetal liver stem
cells; and (b) all tissue was postnatal, possibly with reduced
growth potential as compared with fetal thymus tissue. Against
the latter possibility is the observation that in children who
undergo multiple thoracotomies for corrective cardiovascular
surgery in whom >95% of thymic tissue was removed at
the initial operation, the thymus is frequently observed to
have regenerated by the time of subsequent operations (R.
Ungerleider, Duke University, personal communication).
Presently, experiments are underway to attempt to reconsti-
tute human thymic microenvironment grafts in irradiated
SCID mice with human bone marrow CD7+ T cell pre-
cursors (1, 2) to resolve this issue. Namikawa et al. (60) have
recently reported long-term survival of multilineage hema-
topoietic precursors in fetal thymus grafts implanted with
fetal liver grafts. In contrast to the thymic grafts described
by Namikawa et al. (60) and McCune et al. (8), our thymic
grafts have a dysplastic morphology (Fig. 3). If reconstitu-
tion experiments using T cell precursors in our system does
not promote normal postnatal thymic growth and histogen-
esis, then this could be a major limitation of the SCID-Hu
model using postnatal thymus.
Thus, the use of human postnatal thymic tissue grafts in
immunosuppressed SCID mice provides an easily accessible
model for the study of human thymocyte development and
human thymic microenvironment function. Moreover, study
ofthe mechanisms ofaction ofanti-asialo GM-1 in inducing
T and B cell lymphopoiesis should provide insights into the
cellular control of lymphopoiesis. Finally, study of human/
mouse chimeric thymus grafts in SCID(Ig') anti-asialo
GM-1-treated mice provides a unique model to study evolu-
tionarily conserved mechanisms ofTE-thymocyte interactions.
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